Ipca Laboratories has posted net profit growth of 15.9 per cent during the fourth quarter ended March 2018 to Rs. 51 crore from Rs. 44 crore in the similar period of last year. Its standalone net sales increased by 17.2 per cent to Rs. 784 crore from Rs. 669 crore. EPS improved to Rs. 4.07 from Rs. 3.52 in the last period.

Ipca has registered consolidated net profit growth of 22.6 per cent during the year ended March 2018 to Rs. 239 crore from Rs. 195 crore in the previous year. EBIDTA improved to Rs. 481 crore from Rs. 453 crore. Its consolidated net sales improved by just 2.2 per cent to Rs. 3,284 crore from Rs. 3,212 crore. EPS worked out to Rs. 18.97 from Rs. 15.42 in the last year.

Its domestic sales improved by 1.3 per cent to Rs. 1,617 crore during year ended March 2018 from Rs. 1,596 crore and that in international market increased marginally to Rs. 1,667 crore from Rs. 1,616 crore. Total formulations sales increased by 1.5 per cent to Rs. 2,419 crore from Rs. 2,384 crore and that of APIs increased to Rs. 749 crore from Rs. 710 crore.